Valutazione 4.7 sulla base di 277 voti.
Mean Tmax and mean plasma elimination half-life of albendazole sulfoxide were unchanged. Albendazole sulfoxide plasma concentrations were unchanged 4 hours after dosing.
Trichinosis Worm Infection
Theophylline Following a single dose of albendazole 400 mg, the pharmacokinetics of theophylline aminophylline 5. Albendazole induces cytochrome P450 1A in human hepatoma cells; therefore, Albendazole Italia, it is recommended that plasma concentrations of theophylline be monitored during and after treatment.
Monitor blood Albendazole at Albendazole beginning of each 28-day cycle of therapy, and every 2 weeks while on therapy with ALBENZA in all Italia. Patients with liver disease and patients with hepatic Albendazole are at increased risk for bone marrow suppression and warrant more frequent monitoring of blood counts. Italia Effects ALBENZA may cause fetal Italia and should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. Advise women of reproductive potential to use effective birth control for the duration of ALBENZA therapy and for one month after end of therapy, Albendazole Italia.
Risk Of Neurologic Symptoms In Neurocysticercosis Patients being treated for neurocysticercosis should receive steroid and anticonvulsant therapy to prevent neurological symptoms e.
What is albendazole?
Before initiating therapy for neurocysticercosis, Albendazole Italia, examine the patient for the presence of retinal lesions. If such lesions are visualized, weigh the need for anticysticeral therapy against the possibility of retinal damage resulting from inflammatory damage caused by ALBENZA-induced death Italia the parasite. These elevations have generally returned to normal upon discontinuation of therapy.
Monitor liver enzymes transaminases before the start of each treatment cycle and at least every 2 weeks during treatment. If hepatic enzymes exceed twice the upper limit of normal, consideration should be given to discontinuing ALBENZA Albendazole based on individual patient circumstances, Albendazole Italia. Discontinue therapy if liver enzymes are significantly increased or if clinically significant decreases in blood cell counts occur.
Patients with epidemiologic factors who are at risk for neurocysticercosis should be evaluated prior to initiation of therapy. ALBENZA should not be used in pregnant women except in clinical circumstances where no alternative management is appropriate. ALBENZA has been shown to be teratogenic to cause Albendazole and skeletal malformations in pregnant rats and rabbits.
It is not known whether it is excreted in human milk. Pediatric Use Hydatid disease is uncommon in infants and young children, Albendazole Italia. Geriatric Use In patients aged 65 and older with either hydatid disease or neurocysticercosis, Albendazole Italia, there was insufficient data to determine whether the safety and effectiveness of ALBENZA is different from that of younger Italia.